Evidence map›Paper›PMID 40104234›Full record

GuidelineActa clinica Croatica2024

CROATIAN GUIDELINES FOR SPECIFIC PREVENTIVE TREATMENT OF MIGRAINE WITH MONOCLONAL ANTIBODIES TARGETING CALCITONIN GENE-RELATED PEPTIDE (CGRP) (EPTINEZUMAB, FREMANEZUMAB, AND GALCANEZUMAB) OR THE CGRP RECEPTOR (ERENUMAB).

Davor Jančuljak, Damir Petravić, Darija Mahović Lakušić, Arijana Lovrenčić-Huzjan, Koraljka Bačić Baronica, Marijana Bosnar Puretić, Zlatko Hucika, Marina Titlić, Zvonimir Popović, Zoran Tomić and 2 more

Abstract readPractice GuidelineReview
PubMed Full text at PMC Publisher
In one paragraph

Guideline in Acta clinica Croatica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Davor JančuljakDepartment of Neurology, Osijek University Hospital Center, Osijek, Croatia.
Damir PetravićDepartment of Neurology, Zagreb University Hospital Center, Zagreb, Croatia.
Darija Mahović LakušićDepartment of Neurology, Zagreb University Hospital Center, Zagreb, Croatia.
Arijana Lovrenčić-HuzjanSchool of Medicine, University of Zagreb, Zagreb, Croatia.
Koraljka Bačić BaronicaFaculty of Medicine, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia.
Marijana Bosnar PuretićDepartment of Neurology, Sestre milosrdnice University Hospital Center, Zagreb, Croatia.
Zlatko HucikaDepartment of Neurology, Zabok General Hospital and Hospital for Croatian Veterans, Zabok, Croatia.
Marina TitlićDepartment of Neurology, Split University Hospital Center, Split, Croatia.
Zvonimir PopovićDepartment of Neurology, Osijek University Hospital Center, Osijek, Croatia.
Zoran TomićDepartment of Neurology, Rijeka University Hospital Center, Rijeka, Croatia.
Maristela StojićDepartment of Neurology, Dubrava University Hospital, Zagreb, Croatia.
Vanja Bašić KesFaculty of Medicine, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Calcitonin gene-related peptide (CGRP) plays a key role in the pathophysiology of migraine, acting on CGRP receptors in the trigeminovascular system, causing neurogenic inflammation and vasodilation, and promoting nociception. Four specific monoclonal antibodies targeting CGRP are available for prevention of episodic and chronic migraine in adults with at least four migraine days

Indexed as

Antibodies, MonoclonalCalcitonin Gene-Related PeptideCalcitonin Gene-Related Peptide Receptor AntagonistsMigraine DisordersAntibodies, Monoclonal, HumanizedCroatiaHumansReceptors, Calcitonin Gene-Related PeptideAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedCalcitonin Gene-Related PeptideCalcitonin Gene-Related Peptide Receptor AntagonistseptinezumaberenumabfremanezumabgalcanezumabReceptors, Calcitonin Gene-Related PeptideCalcitonin gene-related peptide (CGRP)EptinezumabErenumabFremanezumabGalcanezumabGuidelinesMigraineMonoclonal antibodyPreventionTreatment

Identifiers

PMID40104234
PMCPMC11912851

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.